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Abstract
Background
Tumor necrosis factor alpha (TNF-α) blockers are recognized as a risk factor for reactivation
of granulomatous infections. Leishmaniasis has been associated with the use of these
drugs, although few cases have been reported.
Methodology
We performed a retrospective observational study including patients with confirmed leish-
maniasis acquired in the Mediterranean basin that were under TNF-α blockers therapy at
the moment of the diagnosis. Patients diagnosed in our hospital from 2008 to 2018 were
included. Moreover, a systematic review of the literature was performed and cases fulfilling
the inclusion criteria were also included.
Principal findings
Forty-nine patients were analyzed including nine cases from our series. Twenty-seven
(55.1%) cases were male and median age was 55 years. Twenty-five (51%) patients were
under infliximab treatment, 20 (40.8%) were receiving adalimumab, 2 (4.1%) etanercept,
one (2%) golimumab and one (2%) a non-specified TNF-α blocker. Regarding clinical pre-
sentation, 28 (57.1%) presented as cutaneous leishmaniasis (CL), 16 (32.6%) as visceral
leishmaniasis (VL) and 5 (10.2%) as mucocutaneous leishmaniasis (MCL). All VL and MCL
patients were treated with systemic therapies. Among CL patients, 13 (46.4%) were treated
with a systemic drug (11 received L-AmB, one intramuscular antimonials and one miltefo-
sine) while 14 (50%) patients were given local treatment (13 received intralesional pentava-
lent antimonials, and one excisional surgery). TNF-α blockers were interrupted in 32
patients (65.3%). After treatment 5 patients (10.2%) relapsed. Four patients with a CL (3
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initially treated with local therapy maintaining TNF-α blockers and one treated with miltefo-
sine) and one patient with VL treated with L-AmB maintaining TNF-α blockers.
Conclusions
This data supports the assumption that the blockage of TNF-α modifies clinical expression
of leishmaniasis in endemic population modulating the expression of the disease leading to
atypical presentations. According to the cases reported, the best treatment strategy would
be a systemic drug and the discontinuation of the TNF-α blockers therapy until clinical
resolution.
Author summary
Tumor necrosis factor alpha (TNF-α) blockers are widely used in numerous inflammatory
diseases such rheumatoid arthritis, psoriasis or inflammatory bowel diseases. They have
been recognized as a risk factor for reactivation of granulomatous infections. Although
few cases have been reported, Leishmaniasis has been associated with the use of these
drugs. Leishmania infantum is the main causative agent of leishmaniasis in Southern
Europe and is prone to produce the visceral form. However, TNF-α has been implicated
in the initial events of the infection mediating the disease expression. In our series, we
have observed a surprisingly high proportion of cutaneous form (32.6%) and muco-cuta-
neous form (10.2%). Clinical outcome observed in this series is also unusual. Four cases
(14.3%) with cutaneous leishmaniasis who received local therapy relapsed. Among
patients with visceral leishmaniasis, one patient who maintained TNF-α blockers therapy
relapsed despite etiological treatment. This data supports the assumption that the blockage
of TNF-α modifies clinical expression of leishmaniasis leading to atypical presentations.
According to the cases reported we proposed as best treatment strategy a systemic drug
and the discontinuation of the TNF-α blockers therapy until clinical resolution.
Introduction
Tumor Necrosis Factor-α (TNF-α) is a crucial cytokine in the inflammatory cascade by acti-
vating the type 1 T helper (Th1) immune response, enhancing the activity of the macrophages
and essential for the formation and maintenance of granulomas [1].
Since TNF-α has been implicated in numerous immune-mediated disorders, the blockage
of this cytokine has been studied as a therapeutic strategy against such diseases. Nowadays, the
anti-TNF based therapy is widely used and approved for the treatment of chronic inflamma-
tory conditions as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, plaque pso-
riasis and psoriatic arthritis, ankylosing spondylitis and inflammatory bowel diseases [2]. The
first approved TNF-α blocker was etanercept (Enbrel) in May 1998 followed by infliximab
(Remicade) in November 1999, adalimumab (Humira) in December 2002, certolizumab (Cin-
zia) in April 2008 and golimumab (Simponi) in April 2009.
Since their first use, the TNF-α blockers were recognized as a risk factor for reactivation of
granulomatous infections such as tuberculosis, intracellular infections such as salmonellosis or
listeriosis and other opportunistic fungal or viral infections [3].
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Leishmaniasis is a parasitic granulomatous infection and it is endemic to South America,
South Asia, Africa and South Europe. The protozoon is an obligate intracellular parasite of
mononuclear phagocytic system cells. The clinical spectrum of leishmaniasis comprises sub-
clinical (asymptomatic), localized (cutaneous) and disseminated infection (cutaneous, mucosal
and visceral). Its clinical expression is determined on one hand by the species and zimodeme
of the parasite and on the other hand by host factors and immune response [4].
Leishmaniasis has been associated with the use of TNF-α blockers, but only few cases have
been reported in the literature, mainly in the Mediterranean basin [5,6]. We report nine more
cases related to the use of TNF-α blockers and systematically review the published cases
acquired in the Mediterranean basin. We also analyze their clinical presentation and discuss
the relationship with immunomodulatory therapy. Finally, a therapeutic approach is
discussed.
Methods
We carried out a retrospective observational study including patients with a diagnosis of leish-
maniasis in its different forms. All patients were under TNF- α blockers and were diagnosed in
our center between 2008 and 2018. We also performed MEDLINE search using the terms
Leishmania, leishmaniasis, TNF-α inhibitors, TNF-α blockers, anti-TNF-α, adalimumab, inflixi-
mab, etanercept, certolizumab and golimumab. No language or time restrictions were applied.
A manual search of the references of the selected manuscript was also performed.
In order to be included in the analysis, cases had to be diagnosed based on direct observa-
tion of amastigotes and/or positive Leishmania polymerase chain reaction (qPCR) of blood,
bone marrow or skin samples.
DNA extraction from blood and bone marrow samples was carried out from 110 μl with sil-
ica–membrane technology (NucliSens easyMAG. Biomerieux. France) and eluted in 110 μl
according to the manufacturer´s instructions. The extraction protocol from skin biopsy was
made in a Magcore Compact (RBC Bioscience. Taiwan) and eluted in 100 μl according to the
manufacturer´s instructions. A duplex qPCR targeted to kinetoplast minicircle DNA of Leish-
mania sp and human RNase P gene (Taq Man Human RNase P detection reagent; Applied
Biosystems) were performed using the primers and probe described previously [7]. Cycling
conditions were a first step of 15 minutes at 95˚C followed by 45 cycles at 95˚C for 15 seconds
and 55˚C for 1 minute. Amplifications were carried out in a CFX Real-Time PCR detection
system (Bio-Rad, Hercules, CA). Leishmania infantum identification was performed by restric-
tion fragment length polymorphism of the internal transcribed spacer regions (ITS-RFLP) in a
reference laboratory.
Patients were classified based on the clinical form as follows: VL when compatible signs
and symptoms and blood or bone marrow samples had a positive culture or Leishmania poly-
merase chain reaction (qPCR). MCL when compatible signs and symptoms and mucose sam-
ples had a positive culture or Leishmania qPCR. CL when compatible signs and symptoms and
cutaneous samples had a positive culture Leishmania qPCR. We assessed the patients’ com-
plete medical records: demographic data, underlying disease, TNF- α blockers therapy, specific
treatment and outcomes were recorded. Cure was defined as an absence of clinical signs after a
minimum follow-up of 1 year after leishmanicidal treatment discontinuation. Unrelated death
was established when a death with no relation to the infection or its treatment occurred during
follow-up. Relapses were defined as reappearance of clinical signs after treatment discontinua-
tion during the first year of follow-up unless relapse occurring after this period can be microbi-
ologically demonstrated. Those cases without relevant information or not well identified were
excluded from analysis.
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Statistical analysis
Categorical variables are expressed as percentages, and numerical data as the mean±SD for
variables with a normal distribution or the median (IQR) for those with a skewed distribution.
Categorical variables were compared with the chi-square test or Fisher exact test, and continu-
ous variables with the Student t or the Mann-Whitney U test, depending on distribution. All
statistical tests were 2-tailed, and significance was set at P< .05. Statistical analyses were per-
formed using SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA).
Ethics statement
Due to its retrospective design, oral consent was obtained by phone contact from the included
patients. The study was approved by the Ethics Committee of Vall d’Hebron Research
Institute.
Results
A total of 33 publications were retrieved in our search including forty cases that fulfilled inclu-
sion criteria [8–39]. Thus, a total of 49 cases were analyzed including our 9 cases (Table 1).
Twenty-seven (55.1%) cases were male and the median age was 55 (range 7–80) years.
Twenty-five (51%) patients were under infliximab treatment at the moment of leishmaniasis
diagnosis, twenty (40.8%) were receiving adalimumab, two (4.1%) were receiving etanercept,
one (2%) golimumab and another one (2%) received a non-specified TNF-α blocker. From
greater to lesser frequency, the underlying disease was psoriatic arthritis in twelve (24.5%)
cases, rheumatoid arthritis in twelve (24.5%) cases, ankylosing spondylitis in nine (18.4%)
cases, Crohn’s diseases in five (10.2%) cases, plaque psoriasis in five (10.2%) cases and rheuma-
toid arthritis with psoriasis, ulcerative colitis, juvenile idiopathic arthritis, giant cell arthritis,
seronegative arthritis and folliculitis decalvans in one case each other. All patients were diag-
nosed in European hospitals and probable place of infection was Spain in thirty-three (67.3%)
cases followed by Greece in five (10.5%) cases, Italy in four (8.2%) cases, France in two (4.1%)
cases, Malta in two (4.1%) cases, Algeria in two (4.1%) cases and Turkey in one (2%) case.
Regarding the clinical presentation, CL was the most frequent form (28 patients, 57.1%),
eighteen cases presenting as a solitary ulcerative lesion and ten cases including one attended in
our hospital who presented multifocal lesions (Fig 1). Sixteen (32.6%) patients presented VL
and five (10.2%) patients had MCL, three in the nasal cavity (Fig 2), one as hyperplasic lesions
around perianal mucosa and one as an infiltrative tumor involving upper lip, hard palate and
nasal septum. Bone marrow aspirate was performed in one patient with MCL and one patient
with CL. Although no amastigotes forms were observed, the patient with MCL had a positive
Leishmania RT-PCR on the bone marrow sample. Identification to the level of species could
be performed in eighteen patients. L. infantum was identified in seventeen cases and one was
reported as L. donovani complex.
All MCL and VL patients were treated with a systemic therapy. Fifteen (71.4%) of them
were treated with liposomal amphotericine B (L-AmB), including one patient treated in com-
bination with intralesional pentavalent antimonials, three (14.3%) patients were treated with
parenteral pentavalent antimonials and one (4.8%) patient with miltefosine. Among CL cases,
thirteen (46.4%) patients received a systemic treatment; eleven were given L-AmB, one intra-
muscular antimonials and one miltefosine. Local treatment was given to fourteen (50%)
patients, thirteen received intralesional pentavalent antimonials, one combined with surgery
and another with cryotherapy and one patient was treated with surgical excision of the lesion.
Only one patient defaulted and did not receive any treatment.
Leishmaniasis in patients treated with tumor necrosis factor alpha antagonists
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In thirty-two (65.3%) cases TNF-α blockers therapy was interrupted. After treatment, four
(8.2%) patients with CL diagnosis relapsed. Three of these cases were initially treated with
local medication and anti-TNF-α was not stopped. After relapse, the three patients received
systemic treatment and anti-TNF-α therapy was discontinued in one patient, all achieving
clinical cure. Another relapsing patient was initially treated with miltefosine and finally cured
with local antimonials therapy. TNF-α blocker therapy was discontinued in both treatment
courses. The last relapsing patient was a VL treated with L-AmB and TNF-α blockers were not
stopped as her rheumatic disease was active presenting a MCL form 20 months after. When
Fig 1. Patient with multiple cutaneous leishmania lesions.
https://doi.org/10.1371/journal.pntd.0007708.g001
Fig 2. Patient with a mucocutaneous leishmaniasis.
https://doi.org/10.1371/journal.pntd.0007708.g002
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comparing clinical cure of CL patients, although statistical significance could not be reached
cure ratios were 92.3% vs. 78.6% (p = 0.6) when patients received systemic treatment or not
and 94.1% vs 70% (p = 0.13) when TNF-α blockers therapy could be stopped or not. Finally,
the patient who did not receive any treatment was lost to follow up. Two (4.1%) patients died:
one patient after a bacterial superinfection in relation to his immunosuppression and the other
patient as a result of a fatal arrhythmia during his treatment with systemic antimonials. Case
presentation, treatment and outcomes are represented in Fig 3.
Discussion
According to the published data, TNF-α blockers based therapy seems to be associated with a
higher risk of infections, at times with a worse outcome [3]. Nevertheless their efficacy in the
management of many chronic inflammatory diseases has reaffirmed its use, representing one
of the major breakthroughs in the treatment of these diseases [40].
L. infantum is the major causative agent of leishmaniasis in Southern Europe and the most
frequent zymodeme is MON 1 [41]. Even though it has been suggested that there are dermato-
tropic and viscerotropic strains, L. infantum is prone to produce the visceral form of disease
and less frequently the cutaneous form. Although different gens have been proposed to con-
tribute to the viscerlalization process, its mechanisms still remains unclear due to the lack of
good animal models [42].
It is also well known that in L. infantum endemic areas there is a frequent natural challenge
to Leishmania parasites, producing circulating parasitemia in the host during an undefined
non-permanent time-span. Some authors have referred to this subclinical form as “asymptom-
atic carriage”. It means that these patients without symptoms have parasite load only detectable
by highly sensitive methods such as RT-PCR [43,44].
Fig 3. Leishmaniasis form, treatment and outcomes of all included patients. CL: cutaneous leishmaniasis, S: solitary lesion; Mx: multiple lesions; L-AmB:
liposomal amphotericine-B; Sb S: systemic sodium tibogluconate; MTF: miltefosine; Mg IL: intralesional meglumine antimoniate; Surg: surgery; TNF: tumor
necrosis factor;Ø no treatment, ¥ deceased. Arrows represent patients who relapsed and its path shows patient initial treatment and TNF-alpha blocker
management.
https://doi.org/10.1371/journal.pntd.0007708.g003
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In southern Europe the prevalence of asymptomatic carriers is remarkably variable (from
0.5% to 48%) depending on the test used for detection [45]. Those data may suggest that there
are natural and frequent challenges between host and parasite in endemic areas, and that an
effective immune system is required to control clinical expression.
While it seems that in mammalian hosts Leishmania species may be able to infect and
develop within non-hematopoietic cells such as fibroblasts it is mostly inside monocyte/mac-
rophage lineage cells where the parasite replicates and develops long-time survival [46]. Since
these cells have a central role in both innate response and acquired immune response as para-
site antigen presenting, Leishmania interferes in an extremely complex manner with the host
immunological response [47].
The role of TNF-α in the pathogenesis of the disease has been widely studied in both
humans and animal models. As innate TNF-α dependant mechanisms drive cell mediated
immunity by activation of CD4+ and CD8+ T cells, TNF-α is known to be fundamental in the
initial control of the infection together with other cytokines such as IL-12 and IFN-γ [48].
These cytokines mediate the development of an effective CD4+ Th1 response which is critical
to control the infection [49,50]. Furthermore, TNF-α and IFN-γ are responsible for activating
leishmanicidal activity of macrophage which is characterized by an increased production of
free oxygen radicals and nitric oxide (NO) as well as inducing infected cells apoptosis [51,52].
In CL, a polarized Th1 response with low Th2 cytokines has been related to infection resis-
tance and disease outcome. Besides, Th1 and Th2 pathways may also modify disease expres-
sion [53]. However, in patients presenting disseminated diseases such as VL, immune
response seems to be a net suppressive-type response. Rather than an inert Th1 type response,
a Th2 / Th1 type response associated with the production of down-regulating cytokines such
as IL-10 and TGF-β seems to be responsible of the persistent inflammation, the hallmark of
clinical leishmaniasis [54,55]. Moreover, regulatory T- and Th17- cells appear to play an
important role in susceptibility and disease resistance [56].
Hence, TNF-α has been implicated in the initial events of the infection, in direct leishmanici-
dal activity and thus controlling the multiplication of the parasite, developing effective acquired
immunity for long term control of the disease as well as mediating the disease expression [47].
The classical VL in Mediterranean countries has been found primarily in children and
HIV/AIDS infected patients with poor immune status. Nowadays VL cases in adults are also
diagnosed among non-VIH immunosuppressed patients [57]. Moreover, CL is less frequent
than VL in some Mediterranean countries as Spain although it may be underreported [58].
Besides, MCL is considered exceptional in the Old World [43]. Anyhow, in our series the pro-
portion of CL and MCL it is surprisingly high.
Clinical outcome observed in this series is unusual. The natural course of CL caused by L.
infantum is benign and trends to heal spontaneously. In fact, if lesions are less than 5 cm in
diameter and are localized in areas where there is no risk of disfiguring or disabling, only a
local wound care is recommended [59]. Four out of twenty-eight (14.3%) cases of CL reported
in this series relapsed despite etiological treatment.
Despite of the natural viscerotropism of L. infantum, the main acquisition of this infection
is through the skin. Besides, in endemic areas there is a high exposure to Leishmania. Although
some studies report up to 48% of prevalence [60], there are only limited cases of CL reported.
Consequently, it may be assumed that within immune-competent individuals, the immunity
of the host is capable to control the infection, even before that it causes any clinical symptoms.
The reactivation of a latent parasitic form from a granulomatous lesion could be a feasible
explanation for those cases. Clinical data from patient number 21 supports this assumption.
This patient was diagnosed with a MCL form (Fig 2) 4 years after a CL in his left ankle demon-
strated by PCR amplification for Leishmania kinetoplastid sequences which healed
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spontaneously. Because of the latency between the first episode and the second one and the
appearance of a distant lesion far from the initial one, the episode was thus considered as a
reactivation in the context of the TNF-α blockers therapy.
Previous series including patients with Old and New world leishmania species showed no con-
sensus regarding treatment in patients under TNF-α blockers [26]. In this series only including
leishmaniasis acquired at Mediterranean basin countries, besides all patients with VL and MCL
were given a systemic therapy, treatments differ considerably. Seventeen (80.9%) patients
received L-AmB at different doses ranging from 25.4mg/Kg to 50mg/Kg divided in 5 to 10 doses,
three patients received pentavalent antimonials and one miltefosine. L-AmB is usually recom-
mended as first-choice treatment of VL offering similar cure-rates than pentavalent antimonial
[61]. Especially, considering that pentavalent antimonials present a worse toxicity profile and
major toxicities such cardiac arrhythmias or prolonged QTc interval that can lead to death as in
case number 20 of our series [62]. Although miltefosine has successfully been used treating VL,
when it comes to L. infantum, a growing number of treatment failures have been published so
further investigation is needed before its systematic recommendation [63]. Concerning CL treat-
ment, approach disparities are even greater. Half patients received systemic treatment with differ-
ent therapies and dose disparity and the other half received local treatment.
As mentioned before, TNF-α plays a key role in the process of controlling infection that
ranges from limiting the replication of the parasite up to eliciting an effective adaptative response.
TNF-α blockers therapy could modulate the immunological response to a less effective control of
the parasite, hence allowing the infection reactivation or more evident disease expression of
newly acquired infections. To this end, patients under treatment with TNF-α blockers have less
effective immune mediated mechanisms to control and eradicate a parasite challenge, ending in a
higher chance to develop classical and non-classical L. infantum presenting forms, that otherwise
it would have caused a transient parasitemia or an aborted local replication. Likewise, the course
and outcome of the disease may be directly affected by the inhibition of TNF- α. Therefore, dis-
continuation of the anti TNF-α therapy seems to play an important role in the treatment success.
Although miltefosine is an excellent option for the New World CL, evidence is scarce for the
treatment of L. infantum infection [64]. Thus, it seems appropriate to limit its use when other
treatment options are not available or have failed.
According to the cases reported, in our opinion the best treatment strategy would be a sys-
temic treatment and the discontinuation of the TNF-α blockers therapy. L-AmB has proved to
have the best safety profile and compelling evidence of its efficacy in immunosuppressed
patients. One of the major concerns is the reintroduction of TNF-α blockers. Taking into
account published information, it seems reasonable reintroducing them once clinical cure has
been achieved ensuring close clinical follow-up and blood RT-PCR. Although there is scarce
information for its recommendation, etanercep or certolizumab have been suggested as a ther-
apeutical option instead of re-introducing other anti-TNF-α monoclonal antibodies due to its
possible lower risk of reactivating leishmaniasis [65–66].
This study has the limitations of any retrospective review study. Although is one of the big-
gest series published on this topic, the scarce number of patients analyzed limits the strength
of the recommendations. We agree with existing reports on the fact that despite of not being a
common disease in our area, leishmaniasis is likely underreported [58]. Finally, with the
results extracted from this study it is not possible to assess the risk of developing clinical leish-
maniasis during anti TNF-α therapy. However, there is enough supporting data for the biolog-
ical plausibility of the influence of the use of such therapy in the appearance of new cases of
clinical leishmaniasis with a switch in the disease expression and outcome. The blockage of
TNF-α could determine the incapacity to control and eradicate the parasite within the granu-
loma playing an important role in increasing the risk of progression to clinical disease.
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Conclusions
The increase in the use of TNF-α antagonist has been associated with the emergence of new
cases of leishmaniasis. The blockage of TNF-α favors the reactivation of latent leishmaniasis
modulating its expression and worsening its clinical outcome.
Once the leishmaniasis is confirmed, systemic drug treatment and the discontinuation of
the TNF-α blockers therapy until clinical recovery seems to be the best therapeutic approach
when possible.
Otherwise, those patients receiving such therapy and coming from endemic areas require a
close monitoring in order to detect early forms and start adequate treatment.
Prospective studies and more participation on declaring existing cases in the adverse events
notification system is required in order to assess the risk of leishmaniasis and other opportu-
nistic diseases related to the use of anti TNF-α treatment more accurately.
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